ArticleFrontiers in pharmacology2025
Prediction of prognosis and immunotherapy response of tryptophan metabolism genes in acute myeloid leukemia.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myeloid leukemia (AML) is an aggressive and heterogeneous disease, associated with significant morbidity and mortality rates. Tryptophan metabolism has been implicated in the development of several tumors. The immune landscape within the tumor microenvironment plays a pivotal role in both leukemogenesis and the determination of patient prognosis. Nonetheless, the influence of tryptophan metabolic patterns and corresponding immune signatures in AML remains largely unclear. Methods: Transcriptomic, genomic, and clinical data from TCGA were analyzed, and GSE71014 was used for external validation. Molecular subtypes were identified via consensus clustering of tryptophan metabolism-related genes (TRPRGs). Immune infiltration was quantified using ESTIMATE. A tryptophan-related prognostic risk score (TRPRS) was constructed using LASSO-Cox regression and evaluated for prognostic performance. Results: We characterized alterations in 39 TRPRGs across AML cohorts and delineated the clinical and tumor microenvironmental features of two molecular subtypes. First, a TRPRG-based scoring system was established, identifying seven candidate genes significantly associated with patient outcomes. After LASSO-Cox regression selection, six genes were incorporated into the final prognostic model, stratify overall survival risk. The TRPRS effectively stratified overall survival in both the TCGA and GEO cohorts and remained an independent prognostic factor after multivariate adjustment. High-TRPRS patients exhibited distinct immune characteristics and differential drug sensitivity patterns. Functional experiments demonstrated that HADH and ECHS1 promote AML cell proliferation and survival. Discussion: Our integrative analysis identified key tryptophan-metabolism-related genes in AML and developed a six-gene TRPRS capable of accurately distinguishing survival risk. This model not only provides mechanistic insights into AML progression but also offers a framework for individualized risk stratification and therapeutic guidance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.